summary: Ibudilast is a new drug which, based on animal and pilot human studies, seems to have some anti-inflammatory properties, and reduce the damage to white matter in the brain, as observed in neurological diseases other than MS. The results of this multicenter, double-blind, phase 2 trial with oral ibudilast for people with relapsing-remitting MS, suggest that although no beneficial effect on the rate of newly active lesions and relapses was observed, ibudilast might act in a neuroprotective way and may have beneficial clinical effects on disability progression.

authors: Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; For the MN166-001 Investigators

source: Neurology. 2010 Mar 3

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: